vTv Therapeutics (VTVT) opened Q1 2026 with reported revenue of US$36.8 million and basic EPS of US$1.94, putting a spotlight on the shift in its income statement after a series of quarterly losses. Over the past year, the company has seen quarterly revenue move from effectively US$0 in early 2025 to US$36.8 million in Q1 2026, while basic EPS has swung from a loss of US$0.77 in Q1 2025 to a profit of US$1.94, indicating a sharp change in how much of each sales dollar is landing on the bottom line. For investors, that kind of margin shift is likely to frame how this latest print is read, especially against expectations for how durable the new profit profile may be.

See our full analysis for vTv Therapeutics.

With the headline numbers on the table, the next step is to set these results against the most widely held stories about vTv Therapeutics to see which narratives fit the data and which ones start to look out of sync.

US$24.1 million net income reshapes the margin picture

• Q1 2026 net income of US$24.1 million on US$36.8 million of revenue contrasts with losses ranging from US$3.6 million to US$8.7 million in each quarter from Q4 2024 through Q4 2025, so the business moved from absorbing costs to generating a profit on its current scale.
• What stands out for the more bullish interpretation is that trailing twelve month net income of US$2.3 million and basic EPS of US$0.23 now sit alongside forecasts that earnings could decline around 20.9% per year over the next three years. This challenges the idea of a straight-line profitability story and suggests recent margin strength may not fully align with that bullish view.
  • Supporters can point to the shift from trailing twelve month losses of US$18.5 million to US$27.0 million through 2024 and early 2025 to a modest trailing profit of US$2.3 million as evidence that the income statement has already changed direction.
  • Critics will focus on the forecast earnings decline and ask whether the Q1 2026 margin profile is repeatable or more of a one off compared with the earlier run of quarterly losses.

Shift from loss to profit in just four quarters

• Basic EPS moved from a loss of US$1.08 in Q3 2025 and US$0.58 in Q4 2025 to a profit of US$1.94 in Q1 2026, while trailing twelve month EPS turned from losses between US$2.93 and US$3.37 through 2024 and early 2025 to a positive US$0.23 by the latest period.
• Bears argue that projected earnings decline of about 20.9% per year over the next three years limits how much weight investors should put on this EPS swing, and that view is partly backed up by the fact that the trailing twelve month profit is still small at US$2.3 million compared with the size of the single quarter. This makes it harder to treat the latest EPS as a settled run rate.
  • The series of quarterly EPS losses between US$0.55 and US$1.08 through 2024 and 2025 shows how quickly the per-share line can move when revenue is minimal.
  • The current US$38.43 share price against analyst targets averaging US$53.33 in the provided data leaves room between price and those expectations, but the forecast decline in earnings means bears can question whether that gap is justified.

P/S of 12.9x sits between peers and wider biotech

• The stock is trading on a P/S of 12.9x, which is cheaper than the cited peer average of 137.5x but higher than the US biotech industry average of 10.6x, so it is positioned between broader sector pricing and a much richer peer group.
• What is interesting for a more cautious take is that this mid pack P/S multiple is being applied after shareholders saw substantial dilution over the past year and with earnings forecast to decline around 20.9% per year. This suggests the valuation is not purely a deep discount story even though analysts in the dataset see around 38.8% upside from the current US$38.43 price to US$53.33.
  • The combination of recent profitability and a P/S above the industry average provides some support for investors who are comfortable paying up for earnings that have turned positive.
  • At the same time, the dilution and projected earnings decline give more cautious investors a concrete reason to treat the current multiple and the implied upside with some care when thinking about risk to their capital.

To see how other investors are weighing this mix of fresh profits, dilution, and valuation, it is worth checking the broader discussion around the stock Curious how numbers become stories that shape markets? Explore Community Narratives

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on vTv Therapeutics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Given the mix of fresh profits, past dilution, and split views on the outlook, it makes sense to check the numbers yourself and move quickly to an informed stance using the 2 key rewards and 3 important warning signs.

See What Else Is Out There

The mix of forecast earnings decline, recent dilution, and a P/S above the wider biotech average suggests a risk that the current profit and valuation profile may not hold.

If you are uneasy about that trade off and want stocks where the balance sheet and fundamentals look sturdier, start comparing ideas using the solid balance sheet and fundamentals stocks screener (44 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.